Clinical Evidence for Subcutaneous Immunotherapy in Advanced Melanoma

In this segment, Dr. Morrison discusses the clinical evidence supporting subcutaneous immunotherapy and explains the concept of noninferiority in the context of advanced melanoma treatment. He describes how clinical trials have compared intravenous and subcutaneous administration of nivolumab, emphasizing that the goal of these studies is to demonstrate that the newer formulation performs similarly to the traditional approach. Drawing on data from a large randomized trial, he highlights that both pharmacologic activity in the body and clinical outcomes, such as tumor response, were comparable between the two methods of administration. Dr. Morrison explains that these findings provide confidence that subcutaneous delivery is not less effective than intravenous therapy. The discussion also touches on how this evidence supports flexibility in clinical practice, including the potential to transition patients from intravenous to subcutaneous therapy or initiate treatment with the subcutaneous approach in appropriate patients with advanced melanoma.